Key Product Details
Leu16-Ala539, with a C-terminal 6-His tag
N-terminal Sequence Analysis
Predicted Molecular Mass
Immobilized rhEphB4 at 2 µg/mL (100 µL/well) can bind rmEphrin-B2/Fc Chimera with a linear range of 0.0780- 5.00 ng/mL.
Formulation, Preparation and Storage
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
Reconstitute at 100 μg/mL in sterile PBS.
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
EphB4, also known as Htk, Myk1, Tyro11, and Mdk2, is a member of the Eph receptor tyrosine kinase family and binds Ephrin-B2. The A and B class Eph proteins have a common structural organization (1 - 4). The human EphB4 cDNA encodes a 987 amino acid precursor that includes a 15 amino acid (aa) signal sequence, a 524 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 427 aa cytoplasmic domain (5). The ECD contains an N-terminal globular domain, a cysteine-rich domain, and two fibronectin type III domains. The cytoplasmic domain contains a juxtamembrane motif with two tyrosine residues which are the major autophosphorylation sites, a kinase domain, and a conserved sterile alpha motif (SAM) (5). Activation of kinase activity occurs after membrane-bound or clustered ligand recognition and binding. The ECD of human EphB4 shares 89% aa sequence identity with mouse EphB4 and 42 - 45% aa sequence identity with human EphB1, 2, and 3. EphB4 is expressed preferentially on venous endothelial cells (EC) and inhibits cell-cell adhesion, chemotaxis, and angiogenesis. Opposing effects are induced by signaling through Ephrin-B2 expressed on arterial EC: adhesion, endothelial cell migration, and vessel sprouting (6). EphB4 singaling contributes to new vascularization by guiding venous EC away from Ephrin-B2 expressing EC. Ephrin-B2 signaling induces arterial EC to migrate towards nascent EphB4 expressing vessels (6). The combination of forward signaling through EphB4 and reverse signaling through Ephrin-B2 promotes in vivo mammary tumor growth and tumor-associated angiogenesis (7). EphB4 promotes the differentiation of megakaryocytic and erythroid progenitors but not granulocytic or monocytic progenitors (8, 9).
- Poliakov, A. et al. (2004) Dev. Cell 7:465.
- Surawska, H. et al. (2004) Cytokine Growth Factor Rev. 15:419.
- Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.
- Davy, A. and P. Soriano (2005) Dev. Dyn. 232:1.
- Bennett, B.D. et al. (1994) J. Biol. Chem. 269:14211.
- Fuller, T. et al. (2003) J. Cell Sci. 116:2461.
- Noren, N.K. et al. (2004) Proc. Natl. Acad. Sci. 101:5583.
- Wang, Z. et al. (2002) Blood 99:2740.
- Inada, T. et al. (1997) Blood 89:2757.
Product Specific Notices for Recombinant Human EphB4 Protein, CF
For research use only